Skip to main content
Premium Trial:

Request an Annual Quote

Reduction in Share Capital, Reverse-Stock Split Approved by Epigenomics Shareholders

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics said this week that its shareholders have approved a reduction of the firm's share capital and a five-for-one reverse-stock split.

Following a general shareholders meeting, during which the two proposals were approved by 99.8 percent of the present and represented voting rights, Epigenomics' share capital will be reduced to €8.8 million ($12.6 million) from €44.1 million ($63.3 million) to be distributed among 8,818,417 shares after the reverse-stock split is carried out.

The German molecular diagnostics firm had proposed the reduction in share capital and the reverse-stock split last month, saying that the difference of €35.3 million in share capital would be credited to the capital reserve, and "would serve in the full amount to offset depreciation and cover other losses."

When Epigenomics released its full-year 2010 earnings results in the spring, in which it reported a 58 percent decline in revenues, it said that within the second half of 2011 its accrued losses could surpass half of its share capital.

Last month, the firm said that first-quarter revenues were flat year over year.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.